Plain-English translation of NCT06144125 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
During heart surgery, some patients bleed more than expected and need help with blood clotting. This trial is testing whether (a powdered clotting factor) works better than (liquid blood product) at stopping bleeding quickly. Both treatments are guided by a special test that measures how well your blood is clotting in real time.
Excessive bleeding during and after heart surgery can be serious and require multiple transfusions. Doctors want to find the fastest, most effective way to restore normal clotting and reduce the amount of blood products patients need.
You likely qualify if…
You likely don't qualify if…
You would be enrolled just before or during your planned heart surgery. During the operation, doctors would perform a special blood clotting test to see if you need clotting support. If you do, you would be randomly assigned to receive either the powdered treatment or the liquid treatment. The main measurement is how quickly your bleeding stops with each treatment.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
South Korea
Post-approval monitoring
Sponsor
Konkuk University Medical Center
Collaborators
Asan Medical Center, Soonchunhyang University Hospital
Enrollment target
~100 participants
Started
March 2026
Primary completion
September 2026
Age range
20 Years – 75 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tae-Yop KIm, MD PhD
Konkuk University Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.